心通医疗-B(02160)发布中期业绩，股东应占亏损216.3万元，同比减少96.17%

Core Viewpoint - The company reported a revenue of 229 million, reflecting a year-on-year increase of 2.67%, while the loss attributable to equity shareholders decreased by 96.17% to 2.163 million [1] Revenue Performance - The increase in revenue is primarily attributed to the ongoing global commercialization of the VitaFlow Liberty® transcatheter aortic valve and its retrievable delivery system, which significantly boosted overseas revenue [1] - The steady progress in the commercialization of the AnchorMan® left atrial appendage occlusion system and the AnchorMan® left atrial appendage guiding system in both China and overseas markets also contributed to revenue growth [1]